André J Scheen. Nat Rev Endocrinol 2020
Times Cited: 34
Times Cited: 34
Times Cited
Times Co-cited
Similarity
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
38
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
38
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
35
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
29
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
26
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
26
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
André J Scheen. Drugs 2015
André J Scheen. Drugs 2015
20
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
20
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
20
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
20
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
17
Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
17
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetologia 2020
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetologia 2020
14
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
11
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
11
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
André J Scheen. Circ Res 2018
André J Scheen. Circ Res 2018
11
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson,[...]. Diabetes Care 2019
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson,[...]. Diabetes Care 2019
11
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
11
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.
A J Scheen. Diabetes Metab 2019
A J Scheen. Diabetes Metab 2019
11
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.
. Diabetes Care 2020
. Diabetes Care 2020
11
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
11
Preventing and treating kidney disease in patients with type 2 diabetes.
Pierre Delanaye, André J Scheen. Expert Opin Pharmacother 2019
Pierre Delanaye, André J Scheen. Expert Opin Pharmacother 2019
20
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
8
Challenging 2019 ESC guidelines for the management of type 2 diabetes.
A J Scheen. Diabetes Metab 2020
A J Scheen. Diabetes Metab 2020
37
Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
André J Scheen. Expert Opin Drug Saf 2020
André J Scheen. Expert Opin Drug Saf 2020
60
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
8
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
8
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra,[...]. JAMA 2019
Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra,[...]. JAMA 2019
8
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Masanori Shimizu, Kunihiro Suzuki, Kanako Kato, Teruo Jojima, Toshie Iijima, Toshimitsu Murohisa, Makoto Iijima, Hidehiro Takekawa, Isao Usui, Hideyuki Hiraishi,[...]. Diabetes Obes Metab 2019
Masanori Shimizu, Kunihiro Suzuki, Kanako Kato, Teruo Jojima, Toshie Iijima, Toshimitsu Murohisa, Makoto Iijima, Hidehiro Takekawa, Isao Usui, Hideyuki Hiraishi,[...]. Diabetes Obes Metab 2019
8
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Robert Puckrin, Marie-Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana H Y Yu, Kristian B Filion. Acta Diabetol 2018
Robert Puckrin, Marie-Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana H Y Yu, Kristian B Filion. Acta Diabetol 2018
8
Understanding and overcoming metformin gastrointestinal intolerance.
Fabrice Bonnet, André Scheen. Diabetes Obes Metab 2017
Fabrice Bonnet, André Scheen. Diabetes Obes Metab 2017
8
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Mako Yasuda-Yamahara, Naoko Takeda, Masami Chin-Kanasaki, Tatsuroh Kaneko, Eric Mayoux,[...]. Cell Metab 2020
Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Mako Yasuda-Yamahara, Naoko Takeda, Masami Chin-Kanasaki, Tatsuroh Kaneko, Eric Mayoux,[...]. Cell Metab 2020
8
Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
Gilbert Ledesma, Guillermo E Umpierrez, John E Morley, Diane Lewis-D'Agostino, Annett Keller, Thomas Meinicke, Sandra van der Walt, Maximilian von Eynatten. Diabetes Obes Metab 2019
Gilbert Ledesma, Guillermo E Umpierrez, John E Morley, Diane Lewis-D'Agostino, Annett Keller, Thomas Meinicke, Sandra van der Walt, Maximilian von Eynatten. Diabetes Obes Metab 2019
27
Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes.
Alan Sinclair, John E Morley, Leo Rodriguez-Mañas, Giuseppe Paolisso, Tony Bayer, Andrej Zeyfang, Isabelle Bourdel-Marchasson, Ulrich Vischer, Jean Woo, Ian Chapman,[...]. J Am Med Dir Assoc 2012
Alan Sinclair, John E Morley, Leo Rodriguez-Mañas, Giuseppe Paolisso, Tony Bayer, Andrej Zeyfang, Isabelle Bourdel-Marchasson, Ulrich Vischer, Jean Woo, Ian Chapman,[...]. J Am Med Dir Assoc 2012
8
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.
Derek LeRoith, Geert Jan Biessels, Susan S Braithwaite, Felipe F Casanueva, Boris Draznin, Jeffrey B Halter, Irl B Hirsch, Marie E McDonnell, Mark E Molitch, M Hassan Murad,[...]. J Clin Endocrinol Metab 2019
Derek LeRoith, Geert Jan Biessels, Susan S Braithwaite, Felipe F Casanueva, Boris Draznin, Jeffrey B Halter, Irl B Hirsch, Marie E McDonnell, Mark E Molitch, M Hassan Murad,[...]. J Clin Endocrinol Metab 2019
8
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects.
Joaquim Silva Custódio, Jarbas Roriz-Filho, Catarina Addobbati Jordão Cavalcanti, Amanda Martins, João Eduardo Nunes Salles. Drugs Aging 2020
Joaquim Silva Custódio, Jarbas Roriz-Filho, Catarina Addobbati Jordão Cavalcanti, Amanda Martins, João Eduardo Nunes Salles. Drugs Aging 2020
100
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
M Angelyn Bethel, Samuel S Engel, Jennifer B Green, Zhen Huang, Robert G Josse, Keith D Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K McGuire,[...]. Diabetes Care 2017
M Angelyn Bethel, Samuel S Engel, Jennifer B Green, Zhen Huang, Robert G Josse, Keith D Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K McGuire,[...]. Diabetes Care 2017
8
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Lawrence A Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K M Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich,[...]. Diabetes Care 2015
Lawrence A Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K M Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich,[...]. Diabetes Care 2015
8
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
W David Strain, Valentina Lukashevich, Wolfgang Kothny, Marie-José Hoellinger, Päivi Maria Paldánius. Lancet 2013
W David Strain, Valentina Lukashevich, Wolfgang Kothny, Marie-José Hoellinger, Päivi Maria Paldánius. Lancet 2013
8
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
8
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
Hao Zhou, Shuyi Wang, Pingjun Zhu, Shunying Hu, Yundai Chen, Jun Ren. Redox Biol 2018
Hao Zhou, Shuyi Wang, Pingjun Zhu, Shunying Hu, Yundai Chen, Jun Ren. Redox Biol 2018
8
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.
F Bonnet, A J Scheen. Diabetes Metab 2018
F Bonnet, A J Scheen. Diabetes Metab 2018
8
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
André J Scheen. Curr Cardiol Rep 2019
André J Scheen. Curr Cardiol Rep 2019
11
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
5
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent,[...]. Clin Kidney J 2018
William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent,[...]. Clin Kidney J 2018
5
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
5
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
Subodh Verma, John J V McMurray. Diabetologia 2018
Subodh Verma, John J V McMurray. Diabetologia 2018
5
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Myat Theingi Swe, Laongdao Thongnak, Krit Jaikumkao, Anchalee Pongchaidecha, Varanuj Chatsudthipong, Anusorn Lungkaphin. Clin Sci (Lond) 2019
Myat Theingi Swe, Laongdao Thongnak, Krit Jaikumkao, Anchalee Pongchaidecha, Varanuj Chatsudthipong, Anusorn Lungkaphin. Clin Sci (Lond) 2019
8
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.